Search - tctmd.com

Displaying 261 - 275 of 275

Sort: Relevancy | Date

News Daily News

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Shelley Wood

July 19, 2016

News Daily News

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

Michael O'Riordan

July 15, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

Caitlin E. Cox

February 08, 2016

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

News Daily News

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Michael O'Riordan

January 12, 2016

News Daily News

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

Shelley Wood

December 16, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

CME

Advertisement

The EU Versus US Lipid Guideline Debate: It’s the Gap That Matters, Experts Say

Sitting Pretty: Only Prolonged Sedentary Time Linked With Incident CVD Risk

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Statins Possibly Protect Against Death, CV Events in Asymptomatic PAD Patients

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

USPSTF Issues Preliminary Recommendations on Statin Use in Primary Prevention

Statins for Aortic Calcification? Imaging Study Reopens Debate Over LDL’s Role in Aortic Valve Disease

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Severe/Resistant Hypercholesterolemia: New Agents Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content